Cargando…

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component

SIMPLE SUMMARY: Relapse as the most common reason for treatment failure after allogeneic hematopoietic stem-cell transplantation (allo-SCT) in myeloid neoplasms usually occurs during the first year post-transplant, but several patients experience late relapse. This retrospective study aimed to chara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Platte, Victoria, Bergmann, Anika, Hildebrandt, Barbara, Wieczorek, Dagmar, Schuler, Esther, Germing, Ulrich, Kaivers, Jennifer, Haas, Rainer, Kobbe, Guido, Schroeder, Thomas, Rautenberg, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776604/ https://www.ncbi.nlm.nih.gov/pubmed/36551729 http://dx.doi.org/10.3390/cancers14246244

Ejemplares similares

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
por: Rautenberg, Christina, et al.
Publicado: (2019)

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
por: Kasprzak, Annika, et al.
Publicado: (2021)

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
por: Kasprzak, A., et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience
por: Jäger, Paul, et al.
Publicado: (2023)

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
por: Silzle, Tobias, et al.
Publicado: (2019)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
por: Boquoi, A., et al.
Publicado: (2022)

Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
por: Geyh, Stefanie, et al.
Publicado: (2018)

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
por: Rautenberg, Christina, et al.
Publicado: (2019)

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
por: Schuler, Esther, et al.
Publicado: (2020)

Cytogenetic features in myelodysplastic syndromes
por: Haase, Detlef
Publicado: (2008)

A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): A case report
por: Schroeder, Thomas, et al.
Publicado: (2008)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients
por: Strapatsas, Judith, et al.
Publicado: (2021)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

Rare Cytogenetic Abnormalities in Myelodysplastic Syndromes
por: Bacher, Ulrike, et al.
Publicado: (2015)

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
por: Zahid, Mohammad Faizan, et al.
Publicado: (2017)

Relapsed Waldenstrom’s Macroglobulinemia and Therapy-Related Myelodysplastic Syndrome with Complex Cytogenetics: A Treatment Dilemma
por: Kalantri, Shreyas, et al.
Publicado: (2023)

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
por: Kuendgen, Andrea, et al.
Publicado: (2018)

Mesenchymal stromal cells in myeloid malignancies
por: Schroeder, Thomas, et al.
Publicado: (2016)

Jumping translocation: an unusual cytogenetic finding in myeloid neoplasm
por: Borri, Daniela, et al.
Publicado: (2022)

Cytogenetic features in primary myelodysplastic syndrome Egyptian patients
por: Elnahass, Yasser, et al.
Publicado: (2018)

Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes
por: Chaubey, Rekha, et al.
Publicado: (2011)

Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?
por: Saumell, Sílvia, et al.
Publicado: (2015)

Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
por: Anwar, Nida, et al.
Publicado: (2017)

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA
por: Garcia-Gisbert, Nieves, et al.
Publicado: (2022)

Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes()
por: Vu, Minh Phuong, et al.
Publicado: (2022)

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR
por: Schulz, Felicitas, et al.
Publicado: (2023)

Advantages and limitations of cytogenetic, molecular cytogenetic, and molecular diagnostic testing in mesenchymal neoplasms
por: Bridge, Julia A.
Publicado: (2008)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations
por: Chicano, María, et al.
Publicado: (2021)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores
por: Căzăceanu, O, et al.
Publicado: (2014)

Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup
por: Ciabatti, Elena, et al.
Publicado: (2017)

Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification
por: Mahmood, Rafia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hmi4qko7a9qor5n794rd8ulq1i